gamma-aminobutyric acid has been researched along with Liver Diseases in 24 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception." | 9.12 | Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. ( Bergasa, NV; Engler, D; Ginsburg, IH; McGee, M, 2006) |
| " Gas-liquid chromatography and a radioreceptor assay were used to measure plasma gamma-aminobutyric acid (GABA) in patients with liver disease and hepatic encephalopathy." | 7.67 | Evidence for gamma-aminobutyric acid as the inhibitor of gamma-aminobutyric acid binding in the plasma of humans with liver disease and hepatic encephalopathy. ( Leek, J; Levy, LJ; Losowsky, MS, 1987) |
| "Gabapentin was associated with an increase in mean HSA, in contrast to the placebo, which was associated with a decrease." | 6.72 | Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. ( Bergasa, NV; Engler, D; Ginsburg, IH; McGee, M, 2006) |
| "Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception." | 6.72 | Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. ( Bergasa, NV; Engler, D; Ginsburg, IH; McGee, M, 2006) |
| "Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception." | 5.12 | Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. ( Bergasa, NV; Engler, D; Ginsburg, IH; McGee, M, 2006) |
| " More specifically, vigabatrin, which is a very useful and well tolerated new antiepileptic drug for refractory partial epilepsy, should be started at a low dosage of 0." | 4.79 | The new anticonvulsant drugs. Implications for avoidance of adverse effects. ( Krämer, G; Schmidt, D, 1994) |
| "Cohen has illustrated that extremely high Gamma-aminobutyric acid (GABA) levels in the urine and blood and high plasma ammonia were observed for an autistic male child diagnosed with infantile autism." | 3.71 | The significance of ammonia/gamma-aminobutyric acid (GABA) ratio for normality and liver disorders. ( Cohen, BI, 2002) |
| "The mechanism of prolongation of sleeping (anesthesia) time after phenobarbital (PB) treatment was assessed in mice with ethionine (ET)-induced liver disorders (ET-treated group)." | 3.69 | Sleeping time after phenobarbital treatment and the brain levels of gamma-aminobutyric acid and phenobarbital at the regaining of righting response point in ethionine-induced liver-disordered mice. ( Kawai, Y; Noguchi, M, 1996) |
| "Recently it has been suggested that gamma-aminobutyric acid (GABA), a potent inhibitory neurotransmitter, may be involved in the pathogenesis of hepatic encephalopathy." | 3.67 | The effect of (a) neomycin and lactulose treatment on systemic and portal serum GABA levels in rats and (b) pH changes on [3H] GABA binding to isolated rat hepatocytes. ( Minuk, GY; Sarjeant, EJ, 1988) |
| " Gas-liquid chromatography and a radioreceptor assay were used to measure plasma gamma-aminobutyric acid (GABA) in patients with liver disease and hepatic encephalopathy." | 3.67 | Evidence for gamma-aminobutyric acid as the inhibitor of gamma-aminobutyric acid binding in the plasma of humans with liver disease and hepatic encephalopathy. ( Leek, J; Levy, LJ; Losowsky, MS, 1987) |
| "Serum levels of GABA (gamma-aminobutyric acid)-like activity were measured by a radioreceptor assay in 22 healthy subjects and 170 patients with liver diseases." | 3.66 | Serum levels of gamma-aminobutyric-acid-like activity in acute and chronic hepatocellular disease. ( Ferenci, P; Hoofnagle, JH; Jones, EA; Kleinberger, G; Schafer, DF, 1983) |
| "4 mg/kg/h was safe and well tolerated by all mild or moderate hepatic impairment subjects and normal hepatic function subjects." | 3.11 | Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment. ( Chen, H; Ding, Y; Hu, Y; Li, C; Li, X; Liu, J; Liu, X; Lou, J; Ma, S; Wang, X; Wu, M; Wu, N; Xuan, C; Yan, P; Zhang, H; Zheng, W; Zhu, X, 2022) |
| "Gabapentin was associated with an increase in mean HSA, in contrast to the placebo, which was associated with a decrease." | 2.72 | Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. ( Bergasa, NV; Engler, D; Ginsburg, IH; McGee, M, 2006) |
| "Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception." | 2.72 | Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. ( Bergasa, NV; Engler, D; Ginsburg, IH; McGee, M, 2006) |
| "Hyperammonemia is necessary for development of the cerebral complications to liver disease including hepatic encephalopathy and cerebral edema but the mechanisms are unclear." | 2.50 | Cerebral effects of ammonia in liver disease: current hypotheses. ( Ott, P; Vilstrup, H, 2014) |
| "Hepatic encephalopathy is a medical phenomenon that is described as a neuropsychiatric manifestation of chronic or acute liver disease that is characterized by psychomotor, intellectual and cognitive abnormalities with emotional/affective and behavioral disturbances." | 2.49 | Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy. ( Cichoż-Lach, H; Michalak, A, 2013) |
| " Finally, gabapentin is a very safe add-on medication." | 2.39 | The new anticonvulsant drugs. Implications for avoidance of adverse effects. ( Krämer, G; Schmidt, D, 1994) |
| " More specifically, vigabatrin, which is a very useful and well tolerated new antiepileptic drug for refractory partial epilepsy, should be started at a low dosage of 0." | 2.39 | The new anticonvulsant drugs. Implications for avoidance of adverse effects. ( Krämer, G; Schmidt, D, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (45.83) | 18.7374 |
| 1990's | 5 (20.83) | 18.2507 |
| 2000's | 2 (8.33) | 29.6817 |
| 2010's | 5 (20.83) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y | 1 |
| Li, X | 1 |
| Liu, J | 1 |
| Chen, H | 1 |
| Zheng, W | 1 |
| Zhang, H | 1 |
| Wu, M | 1 |
| Li, C | 1 |
| Zhu, X | 1 |
| Lou, J | 1 |
| Yan, P | 1 |
| Wu, N | 1 |
| Liu, X | 1 |
| Ma, S | 1 |
| Wang, X | 1 |
| Ding, Y | 1 |
| Xuan, C | 1 |
| Ott, P | 1 |
| Vilstrup, H | 1 |
| Shilpa, J | 2 |
| Paulose, CS | 2 |
| Anju, TR | 1 |
| Ajayan, MS | 1 |
| Parekh, PJ | 1 |
| Balart, LA | 1 |
| Cichoż-Lach, H | 1 |
| Michalak, A | 1 |
| Cohen, BI | 1 |
| Bergasa, NV | 1 |
| McGee, M | 1 |
| Ginsburg, IH | 1 |
| Engler, D | 1 |
| Ferenci, P | 3 |
| Schafer, DF | 2 |
| Kleinberger, G | 1 |
| Hoofnagle, JH | 1 |
| Jones, EA | 2 |
| Jacobs, R | 1 |
| Pappas, SC | 1 |
| Bonkowsky, HL | 1 |
| Schady, W | 1 |
| Schmidt, D | 1 |
| Krämer, G | 1 |
| Noguchi, M | 1 |
| Kawai, Y | 1 |
| Kellermann, K | 1 |
| Soditt, V | 1 |
| Rambeck, B | 1 |
| Klinge, O | 1 |
| Bosman, DK | 1 |
| Deutz, NE | 1 |
| Maas, MA | 1 |
| van Eijk, HM | 1 |
| Smit, JJ | 1 |
| de Haan, JG | 1 |
| Chamuleau, RA | 1 |
| Wang, F | 1 |
| Niu, Z | 1 |
| Li, ZM | 1 |
| Levy, LJ | 2 |
| Losowsky, MS | 2 |
| Watanabe, A | 1 |
| Shiota, T | 1 |
| Takei, N | 1 |
| Nagashima, H | 1 |
| Minuk, GY | 2 |
| Sarjeant, EJ | 2 |
| Stehle, T | 1 |
| Ebner, J | 1 |
| Schmid, R | 1 |
| Häussinger, D | 1 |
| Leek, J | 1 |
| Singh, NK | 1 |
| Thapliyal, A | 1 |
| Jain, AK | 1 |
| Chansuria, JP | 1 |
| Gupta, JP | 1 |
| Srivastava, PK | 1 |
| Partin, JC | 1 |
| Winder, A | 1 |
| Burgess, ED | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Study to Investigate a Single Bolus Dose Followed With a 30 Minute Constant Infusion of HSK3486 on the Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment (Single-Center, Open-label, Parallel-Group)[NCT04145596] | Phase 1 | 24 participants (Actual) | Interventional | 2019-11-14 | Completed | ||
| Study of Gabapentin for the Pruritus of Cholestasis[NCT00058890] | Phase 3 | 15 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for gamma-aminobutyric acid and Liver Diseases
| Article | Year |
|---|---|
Cerebral effects of ammonia in liver disease: current hypotheses.
Topics: Ammonia; Animals; Astrocytes; Blood-Brain Barrier; Brain Edema; Diffusion; Energy Metabolism; gamma- | 2014 |
Ammonia and Its Role in the Pathogenesis of Hepatic Encephalopathy.
Topics: Ammonia; Animals; Astrocytes; Blood-Brain Barrier; Chronic Disease; gamma-Aminobutyric Acid; Glutami | 2015 |
Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.
Topics: Ammonia; Animals; Blood-Brain Barrier; Brain; Brain Edema; gamma-Aminobutyric Acid; Hepatic Encephal | 2013 |
Neurologic manifestations of acute porphyria.
Topics: Acute Disease; Aminolevulinic Acid; Animals; Central Nervous System; Depression; Electrophysiology; | 1982 |
The new anticonvulsant drugs. Implications for avoidance of adverse effects.
Topics: Abnormalities, Drug-Induced; Anemia, Aplastic; Anticonvulsants; Chemical and Drug Induced Liver Inju | 1994 |
2 trials available for gamma-aminobutyric acid and Liver Diseases
| Article | Year |
|---|---|
Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment.
Topics: Area Under Curve; China; gamma-Aminobutyric Acid; Humans; Liver Diseases; Receptors, GABA | 2022 |
Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Amines; Analgesics; Cholestasis; Chronic Disease; Cyclohexanecarboxylic Acids; Double-Blind M | 2006 |
17 other studies available for gamma-aminobutyric acid and Liver Diseases
| Article | Year |
|---|---|
GABA and 5-HT chitosan nanoparticles decrease striatal neuronal degeneration and motor deficits during liver injury.
Topics: Animals; Bromodeoxyuridine; Cell Differentiation; Cell Proliferation; Chitosan; Cytokines; Drug Deli | 2014 |
Increased cortical neuronal survival during liver injury: effect of gamma aminobutyric acid and 5-HT chitosan nanoparticles.
Topics: Animals; Cell Survival; Cerebral Cortex; Chitosan; Drug Therapy, Combination; gamma-Aminobutyric Aci | 2014 |
The significance of ammonia/gamma-aminobutyric acid (GABA) ratio for normality and liver disorders.
Topics: 4-Aminobutyrate Transaminase; Ammonia; Autistic Disorder; gamma-Aminobutyric Acid; Humans; Liver; Li | 2002 |
Serum levels of gamma-aminobutyric-acid-like activity in acute and chronic hepatocellular disease.
Topics: Adult; Animals; gamma-Aminobutyric Acid; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Hepati | 1983 |
Enzymes of cerebral GABA metabolism and synaptosomal GABA uptake in acute liver failure in the rabbit: evidence for decreased cerebral GABA-transaminase activity.
Topics: 4-Aminobutyrate Transaminase; Animals; Cerebral Cortex; Galactosamine; gamma-Aminobutyric Acid; Glut | 1984 |
Sleeping time after phenobarbital treatment and the brain levels of gamma-aminobutyric acid and phenobarbital at the regaining of righting response point in ethionine-induced liver-disordered mice.
Topics: Anesthesia; Anesthesia Recovery Period; Animals; Brain Chemistry; Carcinogens; Chemical and Drug Ind | 1996 |
Fatal hepatotoxicity in a child treated with vigabatrin.
Topics: Anticonvulsants; Child, Preschool; Epilepsy; Fatal Outcome; gamma-Aminobutyric Acid; Humans; Liver D | 1996 |
Amino acid release from cerebral cortex in experimental acute liver failure, studied by in vivo cerebral cortex microdialysis.
Topics: Acute Disease; Amino Acids; Animals; Aspartic Acid; Cerebral Cortex; Dialysis; gamma-Aminobutyric Ac | 1992 |
Plasma gamma-aminobutyric acid in experimental fulminant hepatic failure of rats and its diagnostic value in hepatic encephalopathy.
Topics: Alanine Transaminase; Animals; Chemical and Drug Induced Liver Injury; Galactosamine; gamma-Aminobut | 1990 |
Plasma gamma aminobutyric acid concentrations provide evidence of different mechanisms in the pathogenesis of hepatic encephalopathy in acute and chronic liver disease.
Topics: Acute Disease; Adult; Chronic Disease; Delta Rhythm; Female; gamma-Aminobutyric Acid; Hepatic Enceph | 1989 |
Excitatory and inhibitory amino acid neurotransmitters and ammonia metabolism in hepatic failure rats.
Topics: Ammonia; Animals; Aspartic Acid; Brain; Carbon Tetrachloride Poisoning; gamma-Aminobutyric Acid; Glu | 1985 |
The effect of (a) neomycin and lactulose treatment on systemic and portal serum GABA levels in rats and (b) pH changes on [3H] GABA binding to isolated rat hepatocytes.
Topics: Animals; Common Bile Duct; Disaccharides; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Homeostas | 1988 |
Uptake and catabolism of gamma-aminobutyric acid by the isolated perfused rat liver.
Topics: Animals; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Chromatography, Hig | 1988 |
Evidence for gamma-aminobutyric acid as the inhibitor of gamma-aminobutyric acid binding in the plasma of humans with liver disease and hepatic encephalopathy.
Topics: Chromatography, Gas; GABA Antagonists; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Live | 1987 |
Alterations in plasma and CSF levels of GABA, 5-HT and amino acids in fulminant hepatic failure.
Topics: Adolescent; Adult; Amino Acids, Branched-Chain; Child; Female; gamma-Aminobutyric Acid; Hepatic Ence | 1985 |
Acute hepatic failure in children.
Topics: Acute Disease; Blood-Brain Barrier; Child; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; | 1985 |
Serum gamma-aminobutyric acid (GABA) levels in patients with hepatic encephalopathy.
Topics: Ammonia; Chronic Disease; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Kidney Failure, C | 1985 |